Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Overall Project Summary The post-antibiotic era has arrived; the current antimicrobial-resistance (AMR) pandemic will expand along with dire outcomes of wide-spread morbidity and mortality. Chemical antibiotics have been, and continue to be, a class of wonder drugs that have saved millions of lives. Unfortunately, their continued efficacy is challenged by the emergence of antimicrobial resistant (AMR) bacterial pathogens. Our ability to develop new antibiotics faster than AMR emerges among pathogens has failed and many experts expect we will experience a return to a pre- antibiotic era in which we cannot treat what are now curable bacterial infections. Therefore, novel, non-antibiotic approaches to controlling bacterial infections are required, and urgently need to be explored and developed. Many of the top AMR killers globally first colonize human mucosal surfaces as a prerequisite for causing infection. The unifying theme of the BCM CARBIRU is to use microbiome-based approaches to control AMR colonization and infections at human mucosal surfaces (intestinal, nasal, bladder, and vaginal). We will investigate the ecological principles of microbial community inhibition of pathogen colonization as well as the use of bacteriophage for precision elimination of bacterial pathobionts. Both approaches have advantages over antibiotics in that they protect the native microbiome, avoiding the elimination of commensal/beneficial microbes along with the pathogens targeted by antimicrobials. We propose four projects, supported by two scientific cores and an administrative core, to explore and optimize microbiome-based strategies for the prevention and treatment of bacterial infections. Project 1. Specialized Phage for ExPEC Decolonization and Therapy. Project 2. Combatting AMR Infections through Biotherapeutic Nasal Decolonization. Project 3. Precision strategies to eradicate AMR pathogens from the vaginal mucosa. Project 4. Defined microbial community to suppress multiple AMR enteric pathogens. These projects are each supported by two scientific cores: a Microbial & Phage Cultivation Core that provides complex bacterial community cultivation, discovers new phage, and provides phage evolution capacity; and an Organoid Cultivation Core that provides unparalleled model systems to study human mucosal surfaces, with and without innate immune cells. We will accomplish two main outcomes. First, we will define and understand the ecological principles that are key for microbial communities and bacteriophage to function to control pathogens at mucosal surfaces. Second, we will identify actionable phage and defined bacterial communities that will be available for testing in human clinical trials at the end of the overall project period. Together, the BCM CARBIRU will capitalize on naturally protective mechanisms at human mucosal surfaces, which have existed for millennia prior to modern medicine, as we enter the era of microbiome-based therapies.
Grant Summary
Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $2.4M for university, nonprofit, healthcare org. Applications are due 2031-04-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $2.4M
2031-04-30
- 1Confirm your organization is eligible for Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces: Frequently Asked Questions
Who is eligible for the Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces?
Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces provide?
Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces provides up to $2.4M per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces deadline?
Applications for Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces are due 2031-04-30 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces?
To apply for Advancing multimodal biologics to combat antibiotic resistance at mucosal surfaces, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.